Beihai Gofar Chuanshan Biological Co., Ltd. Share Price

Equities

600538

CNE000001DD2

Pharmaceuticals

End-of-day quote Shanghai S.E. 03:30:00 29/04/2024 am IST 5-day change 1st Jan Change
4.63 CNY -0.22% Intraday chart for Beihai Gofar Chuanshan Biological Co., Ltd. -4.14% -0.22%

Financials

Sales 2022 460M 63.57M 5.3B Sales 2023 369M 51.05M 4.26B Capitalization 2.43B 336M 28.06B
Net income 2022 34M 4.7M 392M Net income 2023 -82M -11.34M -946M EV / Sales 2022 4.81 x
Net cash position 2022 156M 21.62M 1.8B Net cash position 2023 139M 19.28M 1.61B EV / Sales 2023 6.21 x
P/E ratio 2022
64.6 x
P/E ratio 2023
-29 x
Employees 501
Yield 2022 *
-
Yield 2023
-
Free-Float 66.14%
More Fundamentals * Assessed data
Dynamic Chart
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Beihai Gofar Chuanshan Biological Gets Patent for Extraction Module MT
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Beihai Gofar Chuanshan Biological Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Beihai Gofar Chuanshan Biological Co., Ltd. announced that it has received CNY 12.427005 million in funding CI
Eastern Pioneer Driving School : China stocks edge higher on energy, transport gains RE
Beihai Gofar Marine Biological Industry Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2020 CI
More news
1 day-0.22%
1 week-4.14%
Current month-2.94%
1 month-2.94%
3 months+0.43%
6 months+6.93%
Current year-0.22%
More quotes
1 week
4.59
Extreme 4.59
4.99
1 month
4.31
Extreme 4.31
5.34
Current year
3.20
Extreme 3.2
5.34
1 year
3.20
Extreme 3.2
5.34
3 years
3.20
Extreme 3.2
10.76
5 years
3.20
Extreme 3.2
10.76
10 years
3.06
Extreme 3.06
19.58
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 25/09/25
Director of Finance/CFO 57 18/10/18
Director/Board Member 59 01/01/01
Members of the board TitleAgeSince
Director of Finance/CFO 57 18/10/18
Chief Executive Officer 60 25/09/25
Director/Board Member 52 17/21/17
More insiders
Date Price Change Volume
29/24/29 4.63 -0.22% 6,122,520
26/24/26 4.64 -3.33% 6,425,500
25/24/25 4.8 -1.44% 9,943,700
24/24/24 4.87 +0.62% 12,329,080
23/24/23 4.84 +0.21% 5,442,982

End-of-day quote Shanghai S.E., April 29, 2024

More quotes
Beihai Gofar Chuanshan Biological Co Ltd, formerly Beihai Gofar Marine Biological Industry Co Ltd, is a China-based company mainly engaged in the production and sales of pharmaceutical products and pesticide products. The Company is mainly engaged in the Pharmaceutical Distribution segment, the Pharmaceutical Manufacturing segment, the Deoxyribonucleic Acid Identification and Service segment, and the Other segment. The Company is mainly engaged in pharmaceutical manufacturing and pharmaceutical distribution industries, molecular medical imaging centers, tumor radiotherapy centers, and tumor telemedicine technical services, molecular diagnostics and judicial identification technical services. The Company mainly sells its products in the domestic market.
More about the company
  1. Stock Market
  2. Equities
  3. 600538 Stock